Maze Therapeutics (MAZE) Net Cash Flow (2024 - 2026)

Maze Therapeutics has reported Net Cash Flow for 3 years, with the latest figure at $9.5 million in Q1 2026.

• Quarterly Net Cash Flow fell 90.24% year-over-year to $9.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$95.6 million (down 136.17% YoY) and the FY2025 annual result came in at -$7.6 million, down 104.51% from the prior year.
• Net Cash Flow climbed to $9.5 million in Q1 2026 per MAZE's latest filing, from -$127.5 million in the prior quarter.
• Over five years, Net Cash Flow peaked at $145.0 million in Q2 2024 and troughed at -$127.5 million in Q4 2025.
• A 3-year average of $18.8 million and a median of $9.5 million in 2026 frame the typical range for Net Cash Flow.
• The widest YoY moves for Net Cash Flow: up 11178.96% in 2025, down 370.16% in 2025.
• Over 3 years, Net Cash Flow stood at $47.2 million in 2024, then plunged by 370.16% to -$127.5 million in 2025, then jumped by 107.46% to $9.5 million in 2026.
• According to Business Quant data, Net Cash Flow over the past three periods registered $9.5 million, -$127.5 million, and $52.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.